Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021

Tanner E. Rothstein, Scott A. Cunningham, Rachelle A. Rieke, Jill M. Mainella, Melissa M. Mutchler, Robin Patel

Research output: Contribution to journalArticlepeer-review

Abstract

The epidemiology of macrolide resistance in Mycoplasma (Mycoplasmoides) pneumoniae in the United States is incompletely described. Using a PCR assay targeting common mutations associated with macrolide resistance in M. pneumoniae (23S rRNA gene, A2063G/A2064G), the frequency of macrolide resistance was estimated to be 10% based on analysis of 114 samples tested from January 2014 to September 2021 at Mayo Clinic Laboratories. Seasonality data showed the highest rates of M. pneumoniae infection in the fall/early winter.

Original languageEnglish (US)
JournalAntimicrobial Agents and Chemotherapy
Volume66
Issue number4
DOIs
StatePublished - Apr 2022

Keywords

  • antibiotic resistance
  • macrolides
  • Mycoplasma pneumoniae
  • pneumonia
  • surveillance studies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021'. Together they form a unique fingerprint.

Cite this